At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 473 enrolled
Drug / intervention
rizatriptan benzoate +1 moredrug
Likely dose
rizatriptan benzoate 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Triple-Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of MK462 10 mg p.o. in the Treatment of Multiple Attacks of Migraine Headache
In Brief
A Phase 3 clinical trial evaluating rizatriptan benzoate and Comparator: Placebo for Migraine Headache. Completed, enrolled 473 participants.
Detailed Summary
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 1995
Primary CompletionJan 1996
Study CompletionApr 1996
First PostedMay 2009
TodayJul 2026
First PostedMay 12, 2009
Enrollment StartApr 1, 1995
Primary CompletionJan 1, 1996
Study CompletionApr 1, 1996
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.1 years ago
Interventions
rizatriptan benzoatedrug
Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
Comparator: Placebodrug
Placebo to Rizatriptan, Oral Tablet